Rhapsido

News

Rhapsido is first drug cleared for chronic hives disorder SD

Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include a second indication that causes chronic hives.

News

Novartis sets sights on new oral MS drug after phase 3 wins

Novartis' oral BTK inhibitor remibrutinib has shown efficacy in a pair of phase 3 trials in multiple sclerosis, boosting its blockbuster credentials.

News

Novartis snaps up food allergy firm Excellergy for $2bn

Novartis has signed its second M&A deal in the space of a week, pledging to pay up to $2 billion to acquire US food allergy drug developer Excellergy.

News

Novartis' oral BTK drug moves the needle in CINDU

Novartis is set to expand the label for its oral BTK inhibitor Rhapsido, keeping the drug on course to become one of its biggest-ever brands.

News

FDA clears Novartis' oral drug for chronic hives

Novartis has claimed a first-in-class approval in the US for its oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria.

Rhapsido is first drug cleared for chronic hives disorder SD

Novartis sets sights on new oral MS drug after phase 3 wins

Novartis snaps up food allergy firm Excellergy for $2bn

Novartis' oral BTK drug moves the needle in CINDU

FDA clears Novartis' oral drug for chronic hives

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

Rhapsido

Editor's Picks